Four of six subjects' T-cell lines were expanded in the presence of gag peptides, three were expanded with gp 160 peptides and none were expanded with RT peptides. The anti-HIV CTL activity is defined as the difference between the percentage of specific cytotoxicity against an autologous HIV-expressing target and a lacZ-expressing control target at an E:T ratio of 25:1. The sum of HIV-specific cytotoxicity is the sum of the anti-gp 160, RT, and gag values.

This table gives cross-sectional means and standard deviations for each time point. One subject (226) was missing all week-1 CTL evaluations. The P values give the significance levels for paired comparisons from baseline to the given time point.

The biologic and assay variability, calculated by comparing the two assays on each subject performed before the infusion, was 4% for anti-gp 160–, 3% for anti-RT–, and 5% for anti-gag–specific cytotoxicity.

If only subjects receiving T cells enhanced for anti-gp 160 cytotoxicity are analyzed (subjects 202, 204, and 214), anti-gp 160 cytotoxicity was 23% ± 8% at baseline, 28% ± 7% at week 1, and 28% ± 10% at week 24.

If only subjects receiving T cells enhanced for gag cytotoxicity are analyzed (subjects 204, 216, 203, and 214), anti-gag cytotoxicity was 24% ± 5% at baseline, 28% ± 7% at week 1, and 28% ± 11% at week 24.